Carl Byers
Partner @ F-Prime
Boston, United States
Carl Byers is a Series A investor at F-Prime in Boston focused on Health Care and Software. Carl Byers brings more than 15 years of experience in healthcare to his role as Executive Partner.Carl was on the founding team at athenahealth, Inc. (Nasdaq: ATHN), where he served as Chief Financial Officer from 1997 to 2010. At athenahealth, Carl was responsible for the company's finance, legal and corporate technology teams and served as akey advisor to the CEO as part of the Senior Leadership Team. When a private company, he built the company's financial systems and led seven rounds of equity and subordinated debt financing, raising more than $70 million to support the company's development. Carl led athenahealth's $96 million 2007 Initial Public Offering, which the Wall Street Journal named as the year's most successful. In his tenure, he also held various operational roles at different times. Prior to the founding of athenahealth, Carl was a Senior Consultant in Booz, Allen & Hamilton's New York office, where he worked in the financial services and health insurance industries. Carl teaches entrepreneurial finance at Harvard's Kennedy School where he is an Adjunct Lecturer on Public Policy. He is a director at Lexington Montessori School, a co-trustee of the Bush Trust and an advisor to the Patricelli Center for Social Entrepreneurship at Wesleyan University (CT)
- Total investments:
- 56
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Carl Byers invests in
Stages Carl Byers invests in
Countries Carl Byers invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.1M–$10M
- Series A
- $6.7M–$36M
- Series B
- $11M–$300M
Investment Focus
Industry
- Health Care 28 (50%)
- Software 8 (14%)
- Hospital 7 (13%)
- Information Technology 7 (13%)
- Wellness 6 (11%)
Stage
- Series A 17 (30%)
- Series B 13 (23%)
- Seed 9 (16%)
- Series C 8 (14%)
- Series E 1 (2%)
Country
- United States 29 (52%)
- The Netherlands 1 (2%)
- Trinidad and Tobago 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Almanac Health
|
Almanac Health is a clinical AI platform that brings specialist-grade knowledge to clinicians at the point of care, providing evidence-based clinical decision support across medical specialties, and governed by institutional controls. | $10M / Seed / Mar 16, 2026 | |
| AmplifyMD is a telemedicine platform connecting over 3,300 medical institutions with a lack of specialty access, often in rural or small regions to a network of leading specialists.AmplifyMD provides both the clinical team as well as the software to streamline and automate virtual care delivery and billing workflows and integrates seamlessly withhospitals' existing EHRs. | $20M / Series B / Sep 24, 2025 | ||
| Axle Health provides scheduling and workforce management software for home health care providers. The Axle platform includes a mobile app for clinicians, an operations dashboard for office teams, proprietary logistics algorithms to optimize scheduling, and a patient engagement and booking solution. Axle is integrated with a wide range of EMRs, andthe entire Axle product can be customized and accessed modularly via API. Some of the biggest home health care providers in the country use Axle’s software to improve the utilization of their clinical teams, and automate the operational burden of scheduling and dispatching. | $10M / Series A / May 22, 2025 | ||
| Eleos Health provides automated health tech solutions that accelerate clinicians’ decision-making via an AI-powered Speech-to-Insights system to ensure the provision of personalized and time and cost-effective care. | $60M / Series C / Jan 22, 2025 | ||
| They believe that the no one knows healthcare data better than the healthcare organizations that create it. However, healthcare organizations often lack the tools to generate insights from this data. Statisticians, data scientists and technology gurus can create tools, but these tools have no value until merged with the valuable domain knowledgethat only healthcare organizations possess. They empower healthcare organizations with data science tools to leverage their deep domain knowledge and generate novel insights from their data. | $39M / Series B / Mar 14, 2024 | ||
| Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technologyto enable a simplified experience, and by partnering with top providers for better health outcomes. | $175M / Series E / Dec 29, 2023 | ||
| Doceree is a fully integrated programmatic ad exchange for data-driven marketing, exclusively to physicians. | $35M / Series B / Sep 27, 2023 | ||
| SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize. | $20M / Series A / Mar 16, 2023 | ||
| Spry is a cloud-based operating system that allows movement health professionals to collect and analyze patient data in real time. | $7M / Series A / Jun 22, 2022 | ||
| SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize. | $9M / Seed / Jun 01, 2022 | ||
| See all 56 investments → | |||
Co-Investors
About F-Prime
F-Prime enables companies to turn their boldest ambitions into world-changing breakthroughs in life sciences, technology, healthtech + services, and crypto. Our legacy spans over 50 years, built on the belief that the best investors share the same entrepreneurial spirit of the founders they back—and that conviction still guides us today.Inhealthcare, we focus on therapeutics, medtech, and healthtech + services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech, and crypto. While we’re early-stage investors by choice, we’ll back exceptional teams at any stage.Today, our $4.8 billion under management support breakthroughs across healthcare and technology. Our seasoned team of scientists, engineers, physicians, operators, and investors bring real world expertise to help companies accelerate their path to scalable growth, always with an eye towards a shared vision—achieving something incredible.
F-Prime Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexander Pasteur
Partner
|
|||
Sanjay Aggarwal
Venture Partner
|
|||
Shervin Ghaemmaghami
Operating Partner
|
|||
Stacie Weninger
Executive Director
|
|||
Ben Gorman
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Carl Byers invest in?
Carl Byers invests primarily in Health Care, Software and Hospital startups, most often at Series A and Series B stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Carl Byers invest in?
Carl Byers typically joins rounds of $1.1M–$10M at Seed, $6.7M–$36M at Series A and $11M–$300M at Series B. These are whole funding-round sizes, not Carl Byers's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Carl Byers took part in.
How do I contact Carl Byers?
Public channels for Carl Byers include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Carl Byers last invest?
The most recent investment recorded for Carl Byers closed in Mar 2026. Shizune tracks 56 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
